Expect more megamergers, GSK exec says

Look for more M&A in pharma, GlaxoSmithKline's ($GSK) chief strategy officer says. And not only mergers and buyouts, but megamergers. At Reuters Health Summit, GSK's David Redfern predicted that patent-cliff pressures--and a slowdown of growth in Western markets--will force more pharma companies to join together. "There will probably be more mega-deals," Redfern said. "As pressure increases, you'll probably see more deals."

Count GSK out of any future megamergers, however. Redfern says that his company will stick to its small-deal approach, because it doesn't have the same sort of gaps in its product pipeline as other Big Pharmas do. Given that other drugmakers are also eyeing smaller targets, Redferm expects the market for medium-sized pharma buys to heat up.

GSK is also sticking to its strategy of growing in emerging markets, but it will be looking beyond the big countries--Brazil, Russia, India and China--for future deals. Acquisitions in these "BRIC" countries are getting too competitive. "Prices are being driven up," Redfern says. "We are extremely rational in what we pay."

ALSO: An HIV company set up a year ago by GlaxoSmithKline and Pfizer ($PFE) could be spun off and floated in an initial public offering once its drug pipeline has matured a little further. Report

Suggested Articles

BMS' Opdivo-Yervoy combo is playing in an increasingly crowded space. But the company is leaning on new long-term data to set its regimen apart.

GSK and Alcon have pulled off prescription-to-OTC switches in hopes of giving aging brands Voltaren and Pataday a boost.

Sanofi didn't hesitate to enter Zika vaccine R&D, and despite the associated scandal, the company is again jumping into emerging disease vaccine R…